BioAge Labs Inc BIOA shares are up on Tuesday after the company reported positive Phase 1 data for BGE-102, an oral NLRP3 ...
CRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose levels Phase 2 proof-of-concept trial in cardiovascular risk planned to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results